Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Recruiting Phase 4 Interventional Study
Immunization HPV Infection Human Papillomavirus
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
27 – 45
Sex
Female
Trial phase
Phase 4
Study type
Interventional
Purpose
Prevention
Participants needed
618 (estimated)
Sponsor
The University of Texas Medical Branch, Galveston · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood d…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria: 1. Females 27-45 years old. 2. Ability to give informed consent. 3. Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record. 4. Reliable telephone access for the dura…
Contacts

Abbey B Berenson, MD, PhD

409-772-2417

abberens@utmb.edu

CONTACT

Rosalina M Trujillo

409-747-5594

rmtrujil@utmb.edu

CONTACT